{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:11:35Z","timestamp":1789035095021,"version":"build-2803163510"},"reference-count":154,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Although advances in pediatric oncology have resulted in cure rates exceeding 80% among children with cancer, progress in survival outcomes has begun to plateau in recent years. Mortality in this population remains largely associated with aggressive disease features, particularly tumor resistance to chemotherapy and metastatic spread. At the same time, the growing population of childhood cancer survivors has drawn increasing attention to the persistent and potentially serious late effects associated with conventional chemotherapy. Thus, it is crucial to discover drugs with specific antitumor action, effective and safe drugs that, combined with chemotherapy or radiotherapy, could chemosensitize or radiosensitize the tumor and reduce the severe side effects of both. Substance P (SP) peptide and its Neurokinin-1 receptor (NK-1R) are known to be involved in pediatric cancer, promotion and progression. Pediatric cancer overexpresses SP\/NK-1R and NK-1R is essential for viability of cancer cells and is not essential for normal non-tumor cells. SP induces mitogenesis, exerts anti-apoptotic effects, and promotes angiogenesis, invasion and migration for metastasis in cancer cells and produces inflammation. Conversely, NK-1R antagonists, such as aprepitant and similar drugs, inhibit mitogenesis and induce apoptosis in pediatric cancer cells in a concentration-dependent manner. They also inhibit angiogenesis, invasion, and migration in pediatric cancer cells and have an anti-inflammatory effect. Moreover, aprepitant in combination with chemotherapy or radiotherapy can produce chemosensitization or radiosensitisation and decreases the severe side effects of both. This review updates the role of the SP\/NK-1R axis in pediatric cancers and analyzes its potential as a therapeutic target. It highlights NK-1R antagonists, particularly aprepitant, and their potential as drugs for the treatment of pediatric cancer.<\/jats:p>","DOI":"10.3390\/jcm15187004","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:13:03Z","timestamp":1789031583000},"page":"7004","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7587-0025","authenticated-orcid":false,"given":"Marisa","family":"Rosso","sequence":"first","affiliation":[{"name":"Research Laboratory on Neuropeptides, Institute of Biomedicine of Seville (IBIS), 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1078-1870","authenticated-orcid":false,"given":"Carlos","family":"Alcaide","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hospital Regional Universitario de M\u00e1laga, 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2853-8481","authenticated-orcid":false,"given":"Miguel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Research Laboratory on Neuropeptides, Institute of Biomedicine of Seville (IBIS), 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","first-page":"212","article-title":"Improving the outcome for children with cancer: Development of targeted new agents","volume":"65","author":"Adamson","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","first-page":"315","article-title":"Recent progress in the treatment of cancer in children","volume":"71","author":"Butler","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(96)91015-6","article-title":"The war on cancer","volume":"347","author":"Sporn","year":"1996","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/0019-509X.31164","article-title":"Aprepitant: A substance P antagonist for chemotherapy induced nausea and vomiting","volume":"44","author":"Giri","year":"2007","journal-title":"Indian J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1749-6632.2011.05961.x","article-title":"Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting","volume":"1222","author":"Hargreaves","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jcp.20061","article-title":"The role of substance P in inflammatory disease","volume":"201","author":"Goode","year":"2004","journal-title":"J. Cell. Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz, M., and Cove\u00f1as, R. (2020). The Neurokinin-1 Receptor Antagonist Aprepitant: An Inteligente Bullet against Cancer?. Cancers, 12.","DOI":"10.3390\/cancers12092682"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.npep.2005.03.004","article-title":"The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines","volume":"39","author":"Rosso","year":"2005","journal-title":"Neuropeptides"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1167\/iovs.04-1530","article-title":"Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines","volume":"46","author":"Rosso","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1167\/iovs.05-1591","article-title":"Neurokinin-1 receptors located in human retinoblastoma cell lines: Antitumor action of its antagonist, L-732,138","volume":"48","author":"Rosso","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-010-9594-0","article-title":"The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines","volume":"30","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jhep.2013.12.024","article-title":"Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo","volume":"60","author":"Berger","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3892\/ijo.2013.2164","article-title":"Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts","volume":"44","author":"Berger","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.18632\/oncotarget.13440","article-title":"Targeting tachykinin receptors in neuroblastoma","volume":"8","author":"Henssen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10637-018-0607-8","article-title":"Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists","volume":"37","author":"Piruat","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8082608","DOI":"10.1155\/2022\/8082608","article-title":"The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis","volume":"2022","author":"Alsaeed","year":"2022","journal-title":"BioMed Res. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10637-009-9218-8","article-title":"The NK-1 receptor antagonist aprepitant as a broad-spectrum antitumor drug","volume":"28","author":"Rosso","year":"2010","journal-title":"Investig. New Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","article-title":"Distinct mechanism for antidepressant activity by blockade of central substance P receptors","volume":"281","author":"Kramer","year":"1998","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1124\/jpet.102.043539","article-title":"Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury","volume":"305","author":"Bang","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1471-4159.2002.01155.x","article-title":"Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain","volume":"83","author":"Yu","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"173168","DOI":"10.1016\/j.ejphar.2020.173168","article-title":"A novel effect of Aprepitant: Protection for cisplatin-induced nephrotoxicity and hepatotoxicity","volume":"880","author":"Un","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Legi, A., Rodriguez, E., Eckols, T.K., Mistry, C., and Robinson, P. (2021). Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity. Cancers, 13.","DOI":"10.3390\/cancers13071732"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.2174\/0929867329666220811152602","article-title":"Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?","volume":"30","author":"Robinson","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Covenas, R., and Munoz, M. (2022). Involvement of the Substance P\/Neurokinin-1 Receptor System in Cancer. Cancers, 14.","DOI":"10.3390\/cancers14143539"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00726-014-1736-9","article-title":"Involvement of substance P and the NK-1 receptor in human pathology","volume":"46","year":"2014","journal-title":"Amino Acids"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s11033-018-4387-1","article-title":"Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in endometrial cancer","volume":"45","author":"Gharaee","year":"2018","journal-title":"Mol. Biol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s11033-019-04599-9","article-title":"Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer","volume":"46","author":"Davoodian","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"ref_30","first-page":"491","article-title":"Evaluation of serum substance P level and tissue distribution of NK-1 receptor in papillary thyroid cancer","volume":"12","author":"Asadi","year":"2021","journal-title":"Middle East. J. Cancer"},{"key":"ref_31","first-page":"411","article-title":"Prognostic Significance of Substance P and Neurokinin-1 Receptor in Bladder Cancer","volume":"11","author":"Zahiri","year":"2022","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0026-2862(90)90024-L","article-title":"Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells","volume":"40","author":"Ziche","year":"1990","journal-title":"Microvasc. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0196-9781(84)90020-2","article-title":"Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase","volume":"5","author":"Skidgel","year":"1984","journal-title":"Peptides"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1749-6632.2010.05826.x","article-title":"Neurokinin-1 receptor: Functional significance in the immune system in reference to selected infections and inflammation","volume":"1217","author":"Douglas","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_35","first-page":"495704","article-title":"Biological and Pharmacological Aspects of the NK1-Receptor","volume":"2015","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9475","DOI":"10.1073\/pnas.94.17.9475","article-title":"A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization","volume":"94","author":"Li","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/JLB.3MIR0817-348R","article-title":"Truncation of neurokinin-1 receptor-Negative regulation of substance P signaling","volume":"6","author":"Spitsin","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"ref_38","unstructured":"Robert, V. (2025). Substance P in cancer. Molecular Mediators in Health and Disease: How Cells Communicate, Academic Press."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6291504","DOI":"10.1155\/2022\/6291504","article-title":"The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma","volume":"2022","author":"Munoz","year":"2022","journal-title":"BioMed Res. Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1182\/blood-2003-11-3979","article-title":"Tachykinins regulate the function of platelets","volume":"104","author":"Graham","year":"2004","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/curroncol29010008","article-title":"The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors","volume":"29","author":"Kolorz","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_42","first-page":"6079","article-title":"Expression of truncated neurokinin-1 receptor in childhood neuroblastoma is independent of tumor biology and stage","volume":"37","author":"Pohl","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/092986710790416308","article-title":"A new frontier in the treatment of cancer: NK-1 receptor antagonists","volume":"17","author":"Rosso","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2174\/138945011795528796","article-title":"The NK-1 receptor: A new target in cancer therapy","volume":"12","author":"Rosso","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ijc.2910610608","article-title":"Substance-P receptors in human primary neoplasms: Tumoral and vascular localization","volume":"61","author":"Hennig","year":"1995","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e71148","DOI":"10.1002\/cam4.71148","article-title":"Anti-Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P\/Neurokinin-1 Pathway","volume":"14","author":"Dikmen","year":"2025","journal-title":"Cancer Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11102-024-01490-0","article-title":"Substance P and Neurokinin-1 receptor are overexpressed in adamantinomatous craniopharyngioma than in the pituitary gland","volume":"28","author":"Alcaide","year":"2024","journal-title":"Pituitary"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e0769","DOI":"10.1097\/CAD.0000000000000769","article-title":"Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells","volume":"30","author":"Dikmen","year":"2019","journal-title":"Anticancer Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e28473","DOI":"10.1002\/pbc.28473","article-title":"Neuroblastoma","volume":"68","author":"Chung","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41416-022-01755-0","article-title":"Cellular senescence in neuroblastoma","volume":"126","author":"Zanotti","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Polychronopoulos, P.A., Bedoya-Reina, O.C., and Johnsen, J.I. (2024). The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches. Cancers, 16.","DOI":"10.3390\/cancers16101863"},{"key":"ref_52","first-page":"1969","article-title":"Combined automatic immunological and molecular cytogenetic analysis allows exact identification and quantification of tumor cells in the bone marrow","volume":"7","author":"Luegmayr","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_53","first-page":"297","article-title":"Comparison of the cell immunophenotype of metastatic and primary foci in stage IV-S neuroblastoma","volume":"40","author":"Nowicki","year":"2002","journal-title":"Folia Histochem. Cytobiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"218506","DOI":"10.1016\/j.canlet.2026.218506","article-title":"The paracrine TAC1-TACR1 signaling promotes endothelial senescence and metastatic progression in neuroblastoma","volume":"650","author":"Liu","year":"2026","journal-title":"Cancer Lett."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Gorodezki, D., Schuhmann, M.U., Ebinger, M., and Schittenhelm, J. (2024). Dissecting the Natural Patterns of Progression and Senescence in Pediatric Low-Grade Glioma: From Cellular Mechanisms to Clinical Implications. Cells, 13.","DOI":"10.3390\/cells13141215"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.3390\/curroncol30050379","article-title":"Pediatric Brain Tumours: Lessons from the Immune Microenvironment","volume":"30","author":"Yao","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1007\/s00381-024-06463-z","article-title":"MOST wanted: Navigating the MAPK-OIS-SASP-tumor microenvironment axis in primary pediatric low-grade glioma and preclinical models","volume":"40","author":"Sigaud","year":"2024","journal-title":"Childs Nerv. Syst."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Yvone, G.M., and Breunig, J.J. (2024). Pediatric low-grade glioma models: Advances and ongoing challenges. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1346949"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41698-023-00476-8","article-title":"An untapped window of opportunity for glioma: Targeting therapy-induced senescence prior to recurrence","volume":"7","author":"Carlstrom","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz, M., and Rosso, M. (2025). Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma. Cancers, 17.","DOI":"10.3390\/cancers17030520"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/01.LAB.0000067499.57309.F6","article-title":"Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer","volume":"83","author":"Friess","year":"2003","journal-title":"Lab. Investig."},{"key":"ref_62","first-page":"21","article-title":"Substance P enhances forskolin-stimulated cyclic AMP production in human UC11MG astrocytoma cells","volume":"16","author":"Fowler","year":"1994","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/glia.440060203","article-title":"Functional characterization of neurokinin-1 receptors on human U373MG astrocytoma cells","volume":"6","author":"Eistetter","year":"1992","journal-title":"Glia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10014-005-0178-1","article-title":"Substance P receptor in U373 MG human astrocytoma cells activates mitogen-activated protein kinases ERK1\/2 through Src","volume":"22","author":"Yamaguchi","year":"2005","journal-title":"Brain Tumor Pathol."},{"key":"ref_65","first-page":"4983","article-title":"Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway","volume":"56","author":"Luo","year":"1996","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"26545","DOI":"10.1074\/jbc.M003990200","article-title":"Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells","volume":"275","author":"Castagliuolo","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1054\/bjoc.1999.0946","article-title":"Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft","volume":"8","author":"Palma","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1471-4159.2009.06032.x","article-title":"A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor- mediated apoptosis in glioblastomas","volume":"109","author":"Akazawa","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11060-015-1996-6","article-title":"Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells","volume":"126","author":"Kast","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41572-019-0125-9","article-title":"Craniopharyngioma","volume":"5","author":"Merchant","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrendo.2016.217","article-title":"New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma","volume":"13","author":"Merchant","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_72","first-page":"1163","article-title":"Preserve or sacrifice the stalk? Endocrinological outcomes, extent of resection, and recurrence rates following endoscopic endonasal resection of craniopharyngiomas","volume":"131","author":"Forbes","year":"2018","journal-title":"J. Neurosurg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ebiom.2017.04.013","article-title":"Cellular Senescence: A Translational Perspective","volume":"21","author":"Kirkland","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1007\/s00018-021-03798-7","article-title":"Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis","volume":"78","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12943-025-02405-8","article-title":"From preneoplastic lesion to heterogenous tumor: Recent insights into hepatoblastoma biology and therapeutic opportunities","volume":"24","author":"Yang","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Scurtu, A.M., \u021aarc\u0103, E., Trandafir, L.M., Belu, A., Jehac, A., Martu, I., Bernic, V., Heredea, R.E., \u021aarc\u0103, V., and B\u0103iceanu, D. (2026). Pediatric Hepatoblastoma: From Developmental Molecular Mechanisms to Innovative Therapeutic Strategies. Cancers, 18.","DOI":"10.3390\/cancers18050879"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-025-00620-7","article-title":"Hepatoblastoma","volume":"11","author":"Pio","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1158\/1535-7163.MCT-15-0206","article-title":"Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma","volume":"14","author":"Ilmer","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12964-023-01223-z","article-title":"Retinoblastoma: Present scenario and future challenges","volume":"21","author":"Byroju","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41419-024-07285-2","article-title":"In vitro model of retinoblastoma derived tumor and stromal cells for tumor microenvironment (TME) studies","volume":"15","author":"Alefeld","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Cruz-G\u00e1lvez, C.C., Ordaz-Favila, J.C., Villar-Calvo, V.M., Cancino-Marentes, M.E., and Bosch-Canto, V. (2022). Retinoblastoma: Review and new insights. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.963780"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"156009","DOI":"10.1016\/j.prp.2025.156009","article-title":"Single-cell transcriptomic analyses provide insights into the tumor microenvironment heterogeneity and invasion phenotype in retinoblastoma","volume":"271","author":"Zhang","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41572-022-00416-z","article-title":"Author Correction: Osteosarcoma","volume":"8","author":"Beird","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Lian, H., Zhang, J., Hou, S., Ma, S., Yu, J., Zhao, W., Zhao, D., and Zhang, Z. (2025). Immunotherapy of osteosarcoma based on immune microenvironment modulation. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1498060"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ying, H., Li, Z.Q., Li, M.P., and Liu, W.C. (2023). Metabolism and senescence in the immune microenvironment of osteosarcoma: Focus on new therapeutic strategies. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1217669"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1615\/CritRevOncog.2015013566","article-title":"Biology and Treatment of Rhabdoid Tumor","volume":"20","author":"Geller","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Siada, R., Banerjee, K., Malhotra, P., Ibrahim, M., Moreira, D.C., Prensner, J.R., and Upadhyaya, S.A. (2026). Pediatric Spinal Atypical Teratoid Rhabdoid Tumor: Recent Advances in Biology and Management Options. Cancers, 18.","DOI":"10.3390\/cancers18071171"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.4081\/hr.2021.8847","article-title":"Long-term and quality of survival in patients treated for acute lymphoblastic leukemia during the pediatric age","volume":"13","author":"Devilli","year":"2021","journal-title":"Hematol. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Garcia-Gimenez, A., and Richardson, S.E. (2023). The role of microenvironment in the initiation and evolution of B-cell precursor acute lymphoblastic leukemia. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1150612"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Hughes, A.M., Kuek, V., Kotecha, R.S., and Cheung, L.C. (2022). The Bone Marrow Microenvironment in B-Cell Development and Malignancy. Cancers, 14.","DOI":"10.3390\/cancers14092089"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"14321","DOI":"10.1016\/S0021-9258(18)67021-8","article-title":"Binding characteristics and affinity labeling of protein constituents of the human IM-9 lymphoblast receptor for substance P","volume":"261","author":"Payan","year":"1986","journal-title":"J. Biol. Chem."},{"key":"ref_93","first-page":"33","article-title":"Detection of substance P and its mRNA in human blast cells in childhood lymphoblastic leukaemia using immunocytochemistry and in situ hybridisation","volume":"41","author":"Nowicki","year":"2003","journal-title":"Folia Histochem. Cytobiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/sj.leu.2402920","article-title":"Substance P\u2014A potent risk factor in childhood lymphoblastic leukaemia","volume":"17","author":"Nowicki","year":"2003","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejphar.2016.09.006","article-title":"Inhibition of tachykinin NK-1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt\/p53 axis in pre-B acute lymphoblastic leukemia cells","volume":"791","author":"Bayati","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/CAD.0000000000000591","article-title":"Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: A novel therapeutic potential for aprepitant","volume":"29","author":"Bayati","year":"2018","journal-title":"Anticancer Drugs"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"218621","DOI":"10.1016\/j.canlet.2026.218621","article-title":"Repurposing the Neurokinin-1 Receptor Antagonist Aprepitant to Eradicate Relapsed\/Refractory Acute Lymphoblastic Leukemia via Mitochondria-Driven Necroptosis","volume":"656","author":"Shao","year":"2026","journal-title":"Cancer Lett."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"19635","DOI":"10.1073\/pnas.1908998116","article-title":"Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload","volume":"116","author":"Ge","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Reinhardt, D., Antoniou, E., and Waack, K. (2022). Pediatric Acute Myeloid Leukemia\u2014Past, Present, and Future. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030504"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"104118","DOI":"10.1016\/j.exphem.2023.09.005","article-title":"Microenvironment in acute myeloid leukemia: Focus on senescence mechanisms, therapeutic interactions, and future directions","volume":"129","author":"Guarnera","year":"2024","journal-title":"Exp. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Menter, T., and Tzankov, A. (2022). Tumor Microenvironment in Acute Myeloid Leukemia: Adjusting Niches. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.811144"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1007\/s00277-024-06117-9","article-title":"Immunosuppressive microenvironment in acute myeloid leukemia: Overview, therapeutic targets and corresponding strategies","volume":"103","author":"Zha","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.peptides.2012.09.024","article-title":"The substance P\/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists","volume":"38","author":"Rosso","year":"2012","journal-title":"Peptides"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/labinvest.2010.92","article-title":"The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines","volume":"90","author":"Rosso","year":"2010","journal-title":"Lab. Investig."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3892\/ijo.2014.2565","article-title":"The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer","volume":"45","author":"Carranza","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: Back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1126\/science.2457950","article-title":"Effect of neuropeptides on production of inflammatory cytokines by human monocytes","volume":"241","author":"Lotz","year":"1988","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e13434","DOI":"10.1111\/sji.13434","article-title":"Substance P and neurokinin 1 receptor boost the pathogenicity of granulocyte-macrophage colony-stimulating factor-producing T helper cells in dry eye disease","volume":"101","author":"Rong","year":"2025","journal-title":"Scand. J. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/jlb.65.6.834","article-title":"Substance P primes the formation of hydrogen peroxide and nitric oxide in human neutrophils","volume":"65","author":"Braun","year":"1999","journal-title":"J. Leukoc. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.regpep.2004.07.004","article-title":"Substance P mediates AP-1 induction in A549 cells via reactive oxygen species","volume":"124","author":"Springer","year":"2005","journal-title":"Regul. Pept."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.4049\/jimmunol.176.8.5050","article-title":"Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells","volume":"176","author":"Koon","year":"2006","journal-title":"J. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12038-015-9530-8","article-title":"The substance P\/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs","volume":"40","author":"Esteban","year":"2015","journal-title":"J. Biosci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/jpet.103.050013","article-title":"Enhancement of angiogenesis by endogenous substance P release and neurokinin-1 receptors during neurogenic inflammation","volume":"306","author":"Seegers","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.biocel.2012.04.014","article-title":"Hemokinins modulate endothelium function and promote angiogenesis through neurokinin-1 receptor","volume":"44","author":"Song","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_116","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF)\u2014Key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_117","first-page":"3964","article-title":"Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer","volume":"55","author":"Takahashi","year":"1995","journal-title":"Cancer Res."},{"key":"ref_118","first-page":"e92707","article-title":"Tumor Microenvironment and Its Role in Cancer Progression: An Integrative Review","volume":"17","author":"Almazrouei","year":"2025","journal-title":"Cureus"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0165-5728(97)00167-7","article-title":"Substance P induces secretion of immunomodulatory cytokines by human astrocytoma cells","volume":"81","author":"Palma","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e23638","DOI":"10.1002\/jbt.23638","article-title":"Molecular pathway of pancreatic cancer-associated neuropathic pain","volume":"38","author":"Giri","year":"2024","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/humrep\/dey392","article-title":"Sensory nerve-derived neuropeptides accelerate the development and fibrogenesis of endometriosis","volume":"34","author":"Liu","year":"2019","journal-title":"Hum. Reprod."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"9417","DOI":"10.1038\/s41598-017-09639-7","article-title":"A neuropeptide, Substance-P, directly induces tissue-repairing M2 like macrophages by activating the PI3K\/Akt\/mTOR pathway even in the presence of IFN\u03b3","volume":"7","author":"Lim","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_123","first-page":"113","article-title":"Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor","volume":"89","author":"Schwartz","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/QAD.0000000000000638","article-title":"Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: Phase 1B trial of aprepitant in HIV-1-infected adults","volume":"29","author":"Tebas","year":"2015","journal-title":"AIDS"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.2147\/OTT.S158570","article-title":"Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting","volume":"11","author":"Navari","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/187152008783961932","article-title":"The warburg effect: Why and how do cancer cells activate glycolysis in the presence of oxygen?","volume":"8","year":"2008","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0304-3940(94)91017-0","article-title":"Substance P receptors on human astrocytoma cells are linked to glycogen breakdown","volume":"167","author":"Medrano","year":"1994","journal-title":"Neurosci. Lett."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2337\/diabetes.50.5.937","article-title":"Inhibition of GSK-3 selectively reduces gene expression of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase","volume":"50","author":"Lochhead","year":"2001","journal-title":"Diabetes"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13193-020-01210-7","article-title":"Neuropeptide Substance P Enhances Inflammation-Mediated Tumor Signaling Pathways and Migration and Proliferation of Head and Neck Cancers","volume":"12","author":"Singh","year":"2021","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.matbio.2015.04.004","article-title":"Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature","volume":"44\u201346","author":"Deryugina","year":"2015","journal-title":"Matrix Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/IGC.0000000000000683","article-title":"Substance P Promotes the Progression of Endometrial Adenocarcinoma","volume":"26","author":"Ma","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1083\/jcb.200802081","article-title":"Cell motility through plasma membrane blebbing","volume":"181","author":"Fackler","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1074\/jbc.M808825200","article-title":"Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho\/Rho-associated coiled-coil kinase-dependent mechanism","volume":"284","author":"Meshki","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Meshki, J., Douglas, S.D., Hu, M., Leeman, S.E., and Tuluc, F. (2011). Substance P induces rapid and transient membrane blebbing in U373MG cells in a p21-activated kinase-dependent manner. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025332"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1259\/bjr\/77245199","article-title":"Seeding of tumour cells following breast biopsy: A literature review","volume":"84","author":"Loughran","year":"2011","journal-title":"Br. J. Radiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","article-title":"Surgery for Cancer: A Trigger for Metastases","volume":"77","author":"Tohme","year":"2017","journal-title":"Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrclinonc.2017.194","article-title":"Perioperative events influence cancer recurrence risk after surgery","volume":"15","author":"Hiller","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Yang, Y., Zhou, W., Xu, X., Ge, X., Wang, F., Zhang, G.Q., Miao, L., and Deng, X. (2022). Aprepitant Inhibits JNK and p38\/MAPK to Attenuate Inflammation and Suppresses Inflammatory Pain. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.811584"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Padillo, J., Garc\u00eda, C., S\u00e1nchez, E., Escudero, C., Laga, I., Su\u00e1rez, G., Cepeda, C., Mar\u00edn, L.M., \u00c1lamo, J.M., and Pereira, S. (2026). Association of the neurokinin-1R\/substance P pathway with intraoperative mobilization of tumor cells and early postoperative metastasis in pancreatic cancer. Int. J. Surg., in press.","DOI":"10.1097\/JS9.0000000000005485"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000464353","article-title":"PD-1\/PD-L1 Pathway in Breast Cancer","volume":"40","author":"Stefanovic","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1959270","DOI":"10.1155\/2016\/1959270","article-title":"Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance","volume":"2016","author":"Robinson","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Rodriguez, E., Pei, G., Zhao, Z., Kim, S.T., German, A., and Robinson, P. (2021). Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers, 13, Erratum in Cancers 2021, 13, 5178. https:\/\/doi.org\/10.3390\/cancers13205178.","DOI":"10.3390\/cancers13205178"},{"key":"ref_144","first-page":"8","article-title":"Aprepitant ameliorates cyclophosphamide-induced testicular toxicity in mice via suppression of p38 mitogen-activated protein kinase","volume":"54","author":"Morsy","year":"2025","journal-title":"Mansura Med. J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"124446","DOI":"10.1016\/j.lfs.2026.124446","article-title":"Ameliorative impact of aprepitant on cisplatin testicular toxicity: Dual regulation of PI3K\/AKT pro-survival signaling and Bax\/cytochrome c\/caspase-3 apoptotic signaling","volume":"398","author":"Mohamed","year":"2026","journal-title":"Life Sci."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Aranda, M., T\u00e9llez, T., McKenna, L., and Redondo, M. (2022). Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance. Cancers, 14.","DOI":"10.3390\/cancers14092255"},{"key":"ref_147","unstructured":"FDA (2017). Emend (Aprepitant) Capsule and Oral Suspension Pediatric Postmarketing Pharmacovigilance Review, FDA."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/14740338.2013.804059","article-title":"Safety of neurokinin-1 receptor antagonists","volume":"12","year":"2013","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/bcp.13193","article-title":"Aprepitant in pediatric patients using moderate and highly emetogenic protocols: A systematic review and meta-analyses of randomized controlled trials","volume":"83","author":"Okumura","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/1078155218755547","article-title":"Adverse events associated with aprepitant pediatric bone cancer patients","volume":"25","author":"Okumura","year":"2019","journal-title":"J. Oncol. L. Pharm. Pract."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e35952","DOI":"10.1097\/MD.0000000000035952","article-title":"Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis","volume":"102","author":"Zhang","year":"2023","journal-title":"Medicine"},{"key":"ref_152","first-page":"50","article-title":"Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report","volume":"11","author":"Munoz","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/jnci\/djaf178","article-title":"Aprepitant use during chemotherapy and association with survival in women with early breast cancer","volume":"117","author":"Botteri","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1186\/s40001-026-04624-1","article-title":"Aprepitant exposure and long-term prognosis in breast cancer: A propensity-score-matched cohort study","volume":"31","author":"Pan","year":"2026","journal-title":"Eur. J. Med. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7004\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:44:04Z","timestamp":1789033444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":154,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187004"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187004","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}